Newron Pharmaceuticals S.p.A. (NWPHF)

OTCMKTS · Delayed Price · Currency is USD
12.00
+0.60 (5.26%)
May 15, 2024, 9:30 AM EDT

Newron Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
May '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
177192105303243
Upgrade
Market Cap Growth
83.21%83.21%250.69%-5.67%-26.87%-62.94%
Upgrade
Enterprise Value
224231140473827
Upgrade
Last Close Price
9.369.365.222.102.102.44
Upgrade
PE Ratio
10.7611.72----
Upgrade
PS Ratio
3.323.6110.484.594.846.74
Upgrade
PB Ratio
116.93127.32-3.17-1.998.982.06
Upgrade
P/TBV Ratio
116.93127.32--8.982.06
Upgrade
EV/Sales Ratio
3.714.3413.957.265.774.13
Upgrade
EV/EBITDA Ratio
7.238.52----
Upgrade
EV/EBIT Ratio
7.288.53----
Upgrade
Debt / Equity Ratio
34.6234.62-1.62-3.2513.871.53
Upgrade
Debt / EBITDA Ratio
1.911.91----
Upgrade
Asset Turnover
1.151.150.290.140.110.09
Upgrade
Quick Ratio
2.422.420.625.5010.585.50
Upgrade
Current Ratio
2.602.600.685.6510.795.50
Upgrade
Return on Equity (ROE)
-----146.43%-77.71%
Upgrade
Return on Assets (ROA)
36.44%36.44%-23.05%-18.96%-15.19%-20.26%
Upgrade
Return on Capital (ROIC)
46.45%46.45%-28.99%-21.37%-17.21%-23.21%
Upgrade
Return on Capital Employed (ROCE)
64.80%64.80%----
Upgrade
Earnings Yield
9.29%8.54%-17.09%-62.50%-53.44%-59.23%
Upgrade
FCF Yield
-10.34%-9.50%-10.70%-39.69%-41.12%-44.07%
Upgrade
Buyback Yield / Dilution
-15.30%-15.30%----
Upgrade
Updated Sep 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.